Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1, blast phase chronic myelogenous leukemia, bcr-abl1 positive, blasts more than 5 percent of bone marrow nucleated cells, cd22 positive, philadelphia chromosome positive, bcr-abl1 positive chronic myelogenous leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, refractory chronic myelogenous leukemia, bcr-abl1 positive, interventional, phase1, phase2